<!--'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]]. If this is your first time visiting, we suggest you read the [[tutorial]].'''-->  

Is there a regimen missing from this list?  Would you like to share a different dosage/schedule or an additional reference for a regimen?  Have you noticed an error?  Do you have an idea that will help the site grow to better meet your needs and the needs of many others?  You are [[How_to_contribute|invited to contribute to the site]].
{| class="wikitable" style="text-align:center; width:100%;"
!colspan="4" align="center" style="color:white; font-size:125%; background-color:#31a354"|'''Section editors'''
|-
|style="background-color:#F0F0F0; width:15%"|[[File:Shruti.jpg|frameless|upright=0.3|center]]
|style="width:35%"|<big>[[User:Shrutichaturvedi|Shruti Chaturvedi, MBBS, MSCI]]<br>Baltimore, MD</big><br>[https://www.linkedin.com/in/shruti-chaturvedi-bb83b126/ LinkedIn]
|style="background-color:#F0F0F0; width:15%"|[[File:Tillman_Benjamin-2.jpg|frameless|upright=0.3|center]]
|style="width:35%"|<big>[[User:Benjamintillman|Benjamin Tillman, MD]]<br>Nashville, TN</big>
|-
|}
{| class="wikitable" style="float:right; margin-right: 5px;"
|-
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]]  |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]]  |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
|}
{{TOC limit|limit=3}}
=Guidelines=
==NHLBI==
*'''2014:''' [https://www.nhlbi.nih.gov/health-pro/guidelines/sickle-cell-disease-guidelines/ Evidence-Based Management of Sickle Cell Disease: Expert Panel Report, 2014]

=All lines of therapy=
==Hydroxyurea monotherapy {{#subobject:762af4|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:d87ecd|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM199505183322001 Charache et al. 1995 (MSH)]
|style="background-color:#1a9851"|Phase III (E)
|Placebo
|style="background-color:#1a9850"|Superior annual rate of crises
|-
|}
====Chemotherapy====
*[[Hydroxyurea (Hydrea)]] 15 mg/kg/day PO

''Doses were subsequently adjusted, see article for details.''

===References===
# Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR; Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 1995 May 18;332(20):1317-22. [https://www.nejm.org/doi/full/10.1056/NEJM199505183322001 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/7715639 PubMed]
## '''Update:''' Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003 Apr 2;289(13):1645-51. Erratum in: JAMA. 2003 Aug 13;290(6):756. [http://jama.jamanetwork.com/article.aspx?articleid=196300 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12672732 PubMed]
# '''QoL analysis:''' Ballas SK, Barton FB, Waclawiw MA, Swerdlow P, Eckman JR, Pegelow CH, Koshy M, Barton BA, Bonds DR. Hydroxyurea and sickle cell anemia: effect on quality of life. Health Qual Life Outcomes. 2006 Aug 31;4:59. [http://hqlo.biomedcentral.com/articles/10.1186/1477-7525-4-59 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1569824/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/16942629 PubMed]

==L-glutamine monotherapy {{#subobject:4eb49b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:feca18|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1715971 Niihara et al. 2018 (GLUSCC09-01)]
|style="background-color:#1a9851"|Phase III (E)
|Placebo +/- Hydroxyurea
|style="background-color:#1a9850"|Superior reduction in the number of sickle cell crises through week 48
|-
|}
====Therapy====
*[[L-glutamine (Endari)]] 0.3 g/kg PO twice per day 

'''48-week course'''

===References===
# '''GLUSCC09-01:''' Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP; Investigators of the Phase 3 Trial of l-Glutamine in Sickle Cell Disease. A phase 3 trial of l-glutamine in sickle cell disease. N Engl J Med. 2018 Jul 19;379(3):226-235. [https://www.nejm.org/doi/full/10.1056/NEJMoa1715971 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/30021096 PubMed]

==RBC transfusions==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195437/ DeBaun et al. 2014]
|style="background-color:#1a9851"|Phase III (E)
|Observation
|style="background-color:#91cf60"|Seems to have fewer cerebral infarcts
|-
|}
To be completed
===References===
# DeBaun MR, Gordon M, McKinstry RC, Noetzel MJ, White DA, Sarnaik SA, Meier ER, Howard TH, Majumdar S, Inusa BP, Telfer PT, Kirby-Allen M, McCavit TL, Kamdem A, Airewele G, Woods GM, Berman B, Panepinto JA, Fuh BR, Kwiatkowski JL, King AA, Fixler JM, Rhodes MM, Thompson AA, Heiny ME, Redding-Lallinger RC, Kirkham FJ, Dixon N, Gonzalez CE, Kalinyak KA, Quinn CT, Strouse JJ, Miller JP, Lehmann H, Kraut MA, Ball WS Jr, Hirtz D, Casella JF. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med. 2014 Aug 21;371(8):699-710. [https://www.nejm.org/doi/full/10.1056/NEJMoa1401731 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195437/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25140956 PubMed]

=Investigational agents=
*[[Crizanlizumab (SEG101)]]

[[Category:Sickle cell anemia regimens]]
[[Category:Disease-specific pages]]
[[Category:Hemolytic disorders]]
[[Category:Inherited hemoglobinopathies]]
